EP0833914A4 - Menschliches chemokine beta-11 und alpha-1 - Google Patents

Menschliches chemokine beta-11 und alpha-1

Info

Publication number
EP0833914A4
EP0833914A4 EP96919233A EP96919233A EP0833914A4 EP 0833914 A4 EP0833914 A4 EP 0833914A4 EP 96919233 A EP96919233 A EP 96919233A EP 96919233 A EP96919233 A EP 96919233A EP 0833914 A4 EP0833914 A4 EP 0833914A4
Authority
EP
European Patent Office
Prior art keywords
human chemokine
alpha
beta
human
chemokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96919233A
Other languages
English (en)
French (fr)
Other versions
EP0833914A1 (de
Inventor
Haodong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP0833914A1 publication Critical patent/EP0833914A1/de
Publication of EP0833914A4 publication Critical patent/EP0833914A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
EP96919233A 1995-06-05 1996-06-05 Menschliches chemokine beta-11 und alpha-1 Withdrawn EP0833914A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46440195A 1995-06-05 1995-06-05
US46098795A 1995-06-05 1995-06-05
US464401 1995-06-05
US460987 1995-06-05
PCT/US1996/009572 WO1996039522A1 (en) 1995-06-05 1996-06-05 Human chemokine beta-11 and human chemokine alpha-1

Publications (2)

Publication Number Publication Date
EP0833914A1 EP0833914A1 (de) 1998-04-08
EP0833914A4 true EP0833914A4 (de) 2003-05-28

Family

ID=27039874

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96919233A Withdrawn EP0833914A4 (de) 1995-06-05 1996-06-05 Menschliches chemokine beta-11 und alpha-1

Country Status (7)

Country Link
EP (1) EP0833914A4 (de)
JP (1) JPH11507224A (de)
KR (1) KR19990022283A (de)
CN (1) CN1190991A (de)
AU (1) AU723891B2 (de)
CA (1) CA2222280A1 (de)
WO (1) WO1996039522A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US5633149A (en) * 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6139832A (en) * 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
AU750982B2 (en) * 1995-06-05 2002-08-01 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
AU4243097A (en) * 1996-09-10 1998-04-02 Schering Corporation Mammalian chemokines, related reagents
AU4804697A (en) * 1996-10-04 1998-04-24 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with leukocyte adhesion inhibitor-1 (lai-1), and chemokine beta-11 (ckbeta-11)
AU5410698A (en) * 1996-12-13 1998-07-03 Shionogi & Co., Ltd. Human cc chemokine elc
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
AU1273499A (en) * 1997-10-24 1999-05-17 Human Genome Sciences, Inc. 148 human secreted proteins
KR19990042713A (ko) * 1997-11-27 1999-06-15 허일섭 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법
US6110695A (en) * 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
ATE518884T1 (de) 2002-05-01 2011-08-15 Human Genome Sciences Inc Spezifisch an chemokin beta-4 bindende antikörper
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
KR101919170B1 (ko) 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
EP2820045B1 (de) 2012-03-02 2018-08-22 Vaccinex, Inc. Verfahren zur behandlung von b-zellvermittelten entzündungskrankheiten
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022374A1 (en) * 1995-01-19 1996-07-25 Incyte Pharmaceuticals, Inc. A new chemokine expressed in fetal spleen, its production and uses
WO1996024668A1 (en) * 1995-02-08 1996-08-15 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212073A (en) * 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022374A1 (en) * 1995-01-19 1996-07-25 Incyte Pharmaceuticals, Inc. A new chemokine expressed in fetal spleen, its production and uses
WO1996024668A1 (en) * 1995-02-08 1996-08-15 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAHINDEN C A ET AL: "MONOCYTE CHEMOTACTIC PROTEIN 3 IS A MOST EFFECTIVE BASOPHIL- AND EOSINOPHIL-ACTIVATING CHEMOKINE", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 179, no. 2, 1 February 1994 (1994-02-01), pages 751 - 756, XP000600044, ISSN: 0022-1007 *
DATABASE EMBL [online] 9 February 1995 (1995-02-09), SUDO K ET AL: "Human fetal-lung cDNA 5'-end sequence", XP002223666, Database accession no. D31180 *
LODI P J ET AL: "HIGH-RESOLUTION SOLUTION STRUCTURE OF THE BETA CHEMOKINE HMIP-1BETABY MULTIDIMENSIONAL NMR", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 263, 25 March 1994 (1994-03-25), pages 1762 - 1767, XP002054455, ISSN: 0036-8075 *
See also references of WO9639522A1 *

Also Published As

Publication number Publication date
WO1996039522A1 (en) 1996-12-12
CA2222280A1 (en) 1996-12-12
AU723891B2 (en) 2000-09-07
JPH11507224A (ja) 1999-06-29
EP0833914A1 (de) 1998-04-08
KR19990022283A (ko) 1999-03-25
AU6162896A (en) 1996-12-24
CN1190991A (zh) 1998-08-19

Similar Documents

Publication Publication Date Title
EP0833914A4 (de) Menschliches chemokine beta-11 und alpha-1
IL122428A0 (en) Minizymes and minribozymes and uses thereof
HU9602104D0 (en) Novel medicines and their use
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
GB9500856D0 (en) Composition and use
GB2304309B (en) Laminate and use thereof
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
EP0811059A4 (de) Menschliche chemokine beta-11 und alpha-1
AU5383498A (en) Human chemokine beta-13
EP0836617A4 (de) Parevine und tachyteprine
AU2698795A (en) Human chemokine beta-12
ZA964862B (en) Optimized minizymes and miniribozymes and uses thereof
AU3634595A (en) Bis-oxazolidines and their use
EP0744125A3 (de) Jodkomplex und dessen Verwendung
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU5188296A (en) Carbopeptoids and carbonucleotoids
IL118444A0 (en) Mercapto-triazolyl-silanes their preparation and use
IL122686A0 (en) Benzylhydroxylamines their preparation and use
TW333804U (en) Tableware and tableware cover
ZA951198B (en) Human chemokine beta-11 and human chemokine alpha-1
GB9526407D0 (en) Substances and their uses
AU2002301778A1 (en) Human Chemokine Beta-11 and Human Chemokine Alpha-1
ZA959512B (en) Aryloxycycloalkenyl and aryloxyiminocycloalkenylhy-droxyureas
GB9512703D0 (en) Composition and use
AU2003200072A1 (en) Human chemokine beta-13

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/52 B

Ipc: 7A 61K 38/19 B

Ipc: 7C 07K 14/53 B

Ipc: 7C 12N 15/19 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030409

17Q First examination report despatched

Effective date: 20040518

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040929